Last edition
News about "Korea Disease Control and Prevention Agency (KDCA)"
GC Biopharma's Anthrax Vaccine Shows Safety and Immunogenicity in Phase 2 trial
The Phase 2 clinical trial demonstrated that the anthrax vaccine by GC Biopharma elicited antibodies that neutralised the anthrax toxin at a level exceeding the pre-defined protective threshold. This finding indicates robust immunogenicity and suggests that BARYTHRAX can provide clinically meaningful protection against anthrax infection.
Korea Disease Control And Prevention Agency (KDCA) | 03/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy